» Articles » PMID: 24860576

Characterization of T-bet and Eomes in Peripheral Human Immune Cells

Overview
Journal Front Immunol
Date 2014 May 27
PMID 24860576
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

The T-box transcription factors T-bet and Eomesodermin (Eomes) have been well defined as key drivers of immune cell development and cytolytic function. While the majority of studies have defined the roles of these factors in the context of murine T-cells, recent results have revealed that T-bet, and possibly Eomes, are expressed in other immune cell subsets. To date, the expression patterns of these factors in subsets of human peripheral blood mononuclear cells beyond T-cells remain relatively uncharacterized. In this study, we used multiparametric flow cytometry to characterize T-bet and Eomes expression in major human blood cell subsets, including total CD4(+) and CD8(+) T-cells, γδ T-cells, invariant NKT cells, natural killer cells, B-cells, and dendritic cells. Our studies identified novel cell subsets that express T-bet and Eomes and raise implications for their possible functions in the context of other human immune cell subsets besides their well-known roles in T-cells.

Citing Articles

Thymic development of human natural killer T cells: recent advances and implications for immunotherapy.

Pellicci D, Tavakolinia N, Perriman L, Berzins S, Menne C Front Immunol. 2024; 15:1441634.

PMID: 39267746 PMC: 11390520. DOI: 10.3389/fimmu.2024.1441634.


shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer.

Zhang H, Yao J, Ajmal I, Farooq M, Jiang W Front Immunol. 2024; 15:1369406.

PMID: 38835760 PMC: 11148219. DOI: 10.3389/fimmu.2024.1369406.


The expanding Pandora's toolbox of CD8T cell: from transcriptional control to metabolic firing.

Wu J, Lu Z, Zhao H, Lu M, Gao Q, Che N J Transl Med. 2023; 21(1):905.

PMID: 38082437 PMC: 10714647. DOI: 10.1186/s12967-023-04775-3.


Early-to-mid stage idiopathic Parkinson's disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females.

Capelle C, Cire S, Hedin F, Hansen M, Pavelka L, Grzyb K Nat Commun. 2023; 14(1):7461.

PMID: 37985656 PMC: 10662447. DOI: 10.1038/s41467-023-43053-0.


Immunomodulation and immunopharmacology in heart failure.

Markousis-Mavrogenis G, Baumhove L, Al-Mubarak A, Aboumsallem J, Bomer N, Voors A Nat Rev Cardiol. 2023; 21(2):119-149.

PMID: 37709934 DOI: 10.1038/s41569-023-00919-6.


References
1.
Kondrack R, Harbertson J, Tan J, McBreen M, Surh C, Bradley L . Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med. 2003; 198(12):1797-806. PMC: 2194153. DOI: 10.1084/jem.20030735. View

2.
Cruz-Guilloty F, Pipkin M, Djuretic I, Levanon D, Lotem J, Lichtenheld M . Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med. 2009; 206(1):51-9. PMC: 2626671. DOI: 10.1084/jem.20081242. View

3.
Intlekofer A, Takemoto N, Wherry E, Longworth S, Northrup J, Palanivel V . Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005; 6(12):1236-44. DOI: 10.1038/ni1268. View

4.
Li J, Huston G, Swain S . IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med. 2003; 198(12):1807-15. PMC: 2194161. DOI: 10.1084/jem.20030725. View

5.
Banerjee A, Gordon S, Intlekofer A, Paley M, Mooney E, Lindsten T . Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol. 2010; 185(9):4988-92. PMC: 2975552. DOI: 10.4049/jimmunol.1002042. View